WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
I put my night sweats down to early menopauseHow I kept my Easter under £10 by buying no eggs and using yearVanessa Hudgens displays her baby bump in a tightREVEALED: The truth about viral food influencer Eddie AbbewThe hotel room on WHEELS! SelfDozens of desperate patients queue 'around the block' before 8am for GP appointmentWant a healthy dog? Vets reveal the 10 extreme body conformations owners should AVOID including flatNHS waiting lists fall for fifth month in a row as Rishi Sunak says 'our plan is working'Spotify hikes its prices for millions of UK customers: Premium plans jump by up to 13%Callaghan Innovation wants to cut staff, focus on money
1.8024s , 5763.4296875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Inquest news portal